OUR MEDICAL SPECIALISTS  >  DEPARTMENT OF RADIATION ONCOLOGY & NASOPHARYNGEAL CARCINOMA CENTER

Academician Ma Jun, MD, PhD

Member, Chinese Academy of Sciences · Executive Vice President of SYSUCC  |  Sun Yat-sen University Cancer Center (SYSUCC)

Academician Ma Jun, MD, PhD
MEMBER, CHINESE ACADEMY OF SCIENCES · EXECUTIVE VICE PRESIDENT OF SYSUCC

Academician Ma Jun, MD, PhD

Department of Radiation Oncology & Nasopharyngeal Carcinoma Center
Sun Yat-sen University Cancer Center (SYSUCC)
  • Hospital Affiliation
    Sun Yat-sen University Cancer Center (SYSUCC)
  • Clinical Specialty
    Nasopharyngeal Carcinoma (NPC), IMRT & Head and Neck Radiation
  • Clinical Languages
    English, Mandarin, Cantonese
  • Clinical Experience
    35+ Years
  • Consultation Turnaround
    24–48 Hours Priority Review
Request Specialist Review →
ACCREDITED CHAIR PROFILE & CLINICAL OVERVIEW

World Authority in Nasopharyngeal Carcinoma and Precision Radiotherapy Guidelines

Academician Ma Jun, MD, PhD, is a Member of the Chinese Academy of Sciences, Executive Vice President of Sun Yat-sen University Cancer Center (SYSUCC), and Director of the State Key Laboratory of Oncology in South China. He is universally recognized as the world's preeminent clinical authority on nasopharyngeal carcinoma (NPC).

Academician Ma's clinical trials have directly defined and updated the global NCCN and ASCO/CSCO Clinical Practice Guidelines. His landmark multicenter trial published in *The New England Journal of Medicine* proved that adding gemcitabine + cisplatin (GP) induction chemotherapy prior to concurrent chemoradiotherapy improved 3-year overall survival to 94.6% in locoregionally advanced NPC.

Surgically and dosimetrically, Academician Ma pioneered precision intensity-modulated radiotherapy (IMRT) de-escalation protocols based on circulating EBV-DNA liquid biopsies. By precisely shrinking radiation fields around the brainstem, temporal lobes, auditory apparatus, and salivary glands, his team minimized long-term dry mouth and neurocognitive impairment, achieving world-record 5-year survival rates exceeding 88%.

Primary Appointment Executive Vice President, Sun Yat-sen University Cancer Center (SYSUCC)
Academic Distinction Member, Chinese Academy of Sciences (Elected 2023)
Global Guidelines Leadership Co-Chair, ASCO / CSCO Nasopharyngeal Carcinoma Guidelines Panel; NCCN Guideline Contributor
National Positions Chair, Nasopharyngeal Carcinoma Committee, Chinese Anti-Cancer Association (CACA)
CORE OPERATIVE MASTERY & CLINICAL EXCELLENCE

Procedural Frontiers & Department Innovations

NEJM-Proven GP Induction Chemotherapy

Discovered that gemcitabine + cisplatin induction prior to chemoradiation dramatically eradicates micrometastases and prolongs overall survival.

IMRT Radiation De-Escalation Protocols

Pioneered elective upper neck irradiation de-escalation, sparing low-risk parotid and cervical structures without compromising tumor control.

Circulating EBV-DNA Risk Stratification

Utilizes plasma Epstein-Barr Virus DNA quantification to tailor therapy intensity: intensifying for high-risk and safely sparing toxicity for low-risk.

Re-Irradiation in Recurrent NPC

Engineered specialized hyperfractionated IMRT protocols and particle triage for locally recurrent nasopharyngeal tumors, minimizing carotid blowout risks.

ACADEMIC AWARDS & LANDMARK TREATISES

Distinguished National & International Recognition

N ENGL J MED
Gemcitabine and Cisplatin Induction in Locoregionally Advanced NPC
Landmark trial establishing the premier standard-of-care induction protocol globally.
THE LANCET
Capecitabine Maintenance Therapy in High-Risk Nasopharyngeal Carcinoma
Practice-changing phase III trial proving oral metronomic therapy prevents distant metastasis.
LANCET ONCOL
De-intensified Radiotherapy in Low-Risk Nasopharyngeal Carcinoma
Proved significant toxicity reduction and salivary gland preservation without loss of efficacy.
NATIONAL AWARD
National Science & Technology Progress Award (2nd Class)
Conferred three times by the State Council for transformative advances in nasopharyngeal cancer control.

CASE INTAKE & NPC RADIOTHERAPY TRIAGE

Request an NPC Case Review with Academician Ma Jun, MD, PhD

Submit nasopharynx MRI DICOM scans, baseline and follow-up plasma EBV-DNA copy titers, nasopharyngeal biopsy pathology reports, and systemic staging (PET-CT/Chest CT) for direct review by Academician Ma Jun and the SYSUCC tumor board. Our team responds within 24–48 hours.

    Academician Ma Jun, MD, PhD